Additionally, the combination of αTIGIT with lenalidomide increased CXCR6 gene expression in cytotoxic T cells, which putatively positions these cells to interact with dendritic cells in the tumor microenvironment that provides critical survival signals (48). The gene discussed is CXCR6; the disease is neoplasm.